EchoIQ shares plunged 60% after the FDA issued an NSE notice blocking its heart-failure AI product from the US market. Despite panic selling, strong cash reserves, an active second product, and a management options grant suggest this is a regulatory setback, not a financial collapse.
EchoIQ is expanding its US presence through new funding, partnerships, clinical research, and hospital deployments. Its AI-based cardiac software continues to gain commercial traction, while the chart shows a pullback to key support within a longer-term rising trend.
EchoIQ (ASX: EIQ) has surged on AI-driven healthcare momentum and US expansion, backed by strong clinical results and partnerships. While technically bullish, the stock is consolidating after a sharp rally, with key support at $0.92–$0.95 and resistance near $1.00.
